UA106131C2 - Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання - Google Patents

Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання

Info

Publication number
UA106131C2
UA106131C2 UAA201213609A UAA201213609A UA106131C2 UA 106131 C2 UA106131 C2 UA 106131C2 UA A201213609 A UAA201213609 A UA A201213609A UA A201213609 A UAA201213609 A UA A201213609A UA 106131 C2 UA106131 C2 UA 106131C2
Authority
UA
Ukraine
Prior art keywords
pains
prophylactic
therapeutic agent
diseases associated
urinary organs
Prior art date
Application number
UAA201213609A
Other languages
English (en)
Russian (ru)
Inventor
Акієсі Сомея
Хіроко Хаясіда
Май Кода
Масаюкі Танахасі
Кацуро Йосіока
Original Assignee
Астеллас Фарма Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Інк. filed Critical Астеллас Фарма Інк.
Publication of UA106131C2 publication Critical patent/UA106131C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Пропонується засіб для профілактики або лікування захворювань, які супроводжуються болем в органах сечовипускання, що містить піридильну неароматичну азотовмісну гетероцикло-1-карбоксилатну сполуку формули (І) EMBED MDLDrawOLE.MDLDrawObject.1 (І) або її сіль.
UAA201213609A 2010-04-28 2011-04-27 Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання UA106131C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010104262 2010-04-28
PCT/JP2011/060332 WO2011136308A1 (ja) 2010-04-28 2011-04-27 泌尿器疼痛を伴う疾患の予防又は治療剤

Publications (1)

Publication Number Publication Date
UA106131C2 true UA106131C2 (uk) 2014-07-25

Family

ID=44861604

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201213609A UA106131C2 (uk) 2010-04-28 2011-04-27 Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання

Country Status (14)

Country Link
US (1) US20130030006A1 (uk)
EP (1) EP2564849A4 (uk)
JP (1) JPWO2011136308A1 (uk)
KR (1) KR20130061684A (uk)
CN (1) CN102858340A (uk)
AU (1) AU2011246111B2 (uk)
BR (1) BR112012026876A2 (uk)
CA (1) CA2797420A1 (uk)
EA (1) EA201291122A1 (uk)
MX (1) MX2012012378A (uk)
PH (1) PH12012501890A1 (uk)
TW (1) TW201206440A (uk)
UA (1) UA106131C2 (uk)
WO (1) WO2011136308A1 (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
WO2016033776A1 (en) * 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
AR101696A1 (es) 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
CN110709084A (zh) * 2017-03-13 2020-01-17 阿比德治疗公司 双重magl和faah抑制剂
MX2022007936A (es) * 2019-12-25 2022-10-27 Nippon Shinyaku Co Ltd Agente profilactico y/o terapeutico para la prostatitis cronica/sindrome de dolor pelvico cronico.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271015B1 (en) * 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
MX2007010076A (es) * 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
JP2006306746A (ja) * 2005-04-26 2006-11-09 Astellas Pharma Inc ピリジン−３−イルカルバメート誘導体
EP2049520A4 (en) * 2006-08-07 2011-01-05 Ironwood Pharmaceuticals Inc indole compounds
EA201070451A1 (ru) * 2007-10-10 2010-10-29 Такеда Фармасьютикал Компани Лимитед Амидные соединения
TWI434842B (zh) * 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
RU2011117927A (ru) * 2008-11-06 2012-12-20 Астеллас Фарма Инк. Карбаматное соединение или его соль

Also Published As

Publication number Publication date
EP2564849A4 (en) 2013-11-06
TW201206440A (en) 2012-02-16
WO2011136308A1 (ja) 2011-11-03
US20130030006A1 (en) 2013-01-31
KR20130061684A (ko) 2013-06-11
MX2012012378A (es) 2012-11-16
JPWO2011136308A1 (ja) 2013-07-22
AU2011246111B2 (en) 2014-07-17
AU2011246111A1 (en) 2012-10-18
CA2797420A1 (en) 2011-11-03
EA201291122A1 (ru) 2013-04-30
PH12012501890A1 (en) 2017-07-26
CN102858340A (zh) 2013-01-02
EP2564849A1 (en) 2013-03-06
BR112012026876A2 (pt) 2016-07-19

Similar Documents

Publication Publication Date Title
MX2009010929A (es) Terapias de combinacion que comprenden inhibidores de quinoxalina de pi3k-alfa para uso en el tratamiento del cancer.
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
AU2011328009A8 (en) Compounds and methods for treating pain
NZ706836A (en) Methods of treating cancer
WO2012045090A3 (en) Therapeutic use of a tlr agonist and combination therapy
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
WO2018102687A3 (en) Combination therapy for treating cancer
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
HK1221144A1 (zh) 用於治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
WO2013098416A3 (fr) Composes anti-douleur
EP3590338A3 (en) Medical treatments based on anamorelin
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
PH12012501890A1 (en) Agent for preventing or treating diseases accompanied by urinary pain
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
WO2008156817A8 (en) Renin inhibitors
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2016106357A8 (en) Combination of raf inhibitors and aurora kinase inhibitors
WO2015061777A3 (en) Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema
WO2010081662A3 (en) Methods for identifying patients who will respond well to cancer treatment